We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets close in 5 hours 33 minutes

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.0450-0.0250 (-1.21%)
As of 10:27AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
Previous Close2.0700
Open2.0600
Bid2.0500 x 1100
Ask2.0600 x 4000
Day's Range1.9800 - 2.0698
52 Week Range1.4300 - 10.9910
Volume509,395
Avg. Volume4,267,868
Market Cap227.739M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-2.5500
Earnings DateNov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CHRS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Coherus BioSciences, Inc.
    CHRS: What does Argus have to say about CHRS?COHERUS BIOSCIENCES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Motley Fool

    Why Coherus BioSciences Was Plummeting This Week

    A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of mid-afternoon Friday, according to data compiled by S&P Global Market Intelligence, the healthcare company's share price had fallen by a steep 56% week to date. On Monday after market close, Coherus unveiled a set of third-quarter results that, despite a double-digit revenue increase, missed analyst estimates.

  • Motley Fool

    Why Coherus Biosciences Stock Dropped Today

    Shares of Coherus Biosciences (NASDAQ: CHRS) were down by about 30% as of 3:25 p.m. ET Tuesday after the company announced disappointing third-quarter results and lowered its full-year guidance. It generated $40 million of net sales of Cimerli, which treats retinal conditions -- up 50% from the prior quarter -- and $1.4 million from arthritis treatment Yusimry. Coherus highlighted its recently resubmitted biologic license application for Udenyca OnBody, its on-body injector presentation of Udenyca, after the completion and satisfactory resolution of a Food and Drug Administration (FDA) review of inspection findings at a third-party filler.

  • Insider Monkey

    Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript

    Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Third Quarter 2023 Conference Call. At this time all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be […]

  • Thomson Reuters StreetEvents

    Q3 2023 Coherus BioSciences Inc Earnings Call

    Q3 2023 Coherus BioSciences Inc Earnings Call

  • GlobeNewswire

    Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

    – Net revenue rose 27% from prior quarter to $74.6 million –– CIMERLI® net sales increased 50% to $40 million compared to prior quarter –– LOQTORZI™ now approved with launch planned for the first quarter of 2024 –– Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2023, and recent business highlights: RECENT BUSINESS HIGHL

  • GlobeNewswire

    Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

    – Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug – – Anti-CCR8 antibody, CHS-114, depletes tumor-infiltrating Treg cells and activates NK cells in dissociated head and neck squamous cell carcinoma (HNSCC) tumors – – Anti-PD-1 antibody, LOQTORZI™ (toripalimab-tpzi), exhibits potent T cell activation; in combination with chemotherapy shows enhanced c

  • GlobeNewswire

    Coherus BioSciences to Participate at Upcoming November Investor Conferences

    REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Truist Securities BioPharma Symposium In New York City on Wednesday, November 8, 2023, for 1x1 meetings only.UBS Biopharma Conference in Miami on Thursday, November 9, 2023, a fireside chat presentation at 11:30 a.m. Eastern Time will be webcast.6th Annual Evercore ISI HealthCONx Conference in Mi

  • Zacks

    Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    Vericel Corporation (VCEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

    REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, November 6, 2023, starting at 5:00 p.m. East

  • Motley Fool

    Why Coherus BioSciences Stock Soared Today

    Coherus and Junshi Biosciences announced the long-awaited FDA approval of NPC drug Loqtorzi. Here's what investors need to know.